Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic CD8+ leukemia-associated antigens specific T cells NEXI-001

A preparation of allogeneic CD8+ T cells targeting multiple undisclosed leukemia-associated antigens, with potential immunomodulating and antineoplastic activities. Following peripheral blood mononuclear cell (PBMC) collection from the original stem cell donor and ex vivo priming and expansion, the allogeneic CD8+ leukemia-associated antigens specific T cells NEXI-001 are re-introduced into the leukemia patient, where they target and kill tumor cells expressing these leukemia-associated antigens.
Code name:NEXI 001
NEXI-001
NEXI001
Search NCI's Drug Dictionary